Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07805408) titled 'A Real World Study of Treatment Patterns and Effectiveness of Standard of Care in Primary Immune Thrombocytopenia Patients' on Sept. 1.

Study Type: Observational

Primary Sponsor: Novartis Pharmaceuticals

Condition: Immune Thrombocytopenia

Recruitment Status: Not recruiting

Date of First Enrollment: May 16, 2025

Target Sample Size: 3714

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07805408

Disclaimer: Curated by HT Syndication....